[Skip to Content]
[Skip to Content Landing]
Article
December 1994

A Population StudyMortality and Morbidity After Availability of Surfactant Therapy

Arch Pediatr Adolesc Med. 1994;148(12):1295-1301. doi:10.1001/archpedi.1994.02170120057009
Abstract

Objective:  To assess the impact of recent changes in neonatal intensive care on the mortality and morbidity of very-low-birth-weight neonates (<1501 g).

Design:  Prospective cohort study.

Setting:  Six neonatal intensive care units in Wisconsin and Iowa.

Participants:  All very-low-birth-weight neonates who were admitted to the neonatal intensive care units the year before the availability of exogenous surfactant (n=333), during the investigational new drug protocol for synthetic surfactant (Exosurf) (n=347), and after the release of synthetic surfactant (n=356) (designated as periods 1,2, and 3, respectively).

Interventions:  None.

Main Results:  The percentage of neonates receiving exogenous surfactant in the three periods was 3%, 37%, and 56%, and the percentage receiving antenatal steroids was 12%, 17%, and 27% (P=.0001 for increase in both modalities). The percentage of neonates dying in the three periods was 23%, 14%, and 19% (P=.05 for downward trend). The percentage of neonates with intraventricular hemorrhage decreased in the subgroup weighing between 700 and 1350 g (35%, 28%, and 24%) (P=.04) and increased in the subgroup weighing below 700 g (8%, 41%, and 45%) (P=.03). The percentage of neonates with bronchopulmonary dysplasia increased from 21% to 36% between periods 1 and 2 (P=.003) and decreased to 27% (P=.04) in period 3. Antenatal steroid use was strongly associated with the decrease in intraventricular hemorrhage (odds ratio, 0.35) and mortality risk (odds ratio, 0.20).

Conclusions:  Several developments in care have contributed to changes in mortality risk, incidence of intraventricular hemorrhage, and the severity of respiratory disease in very-low-birth-weight infants.(Arch Pediatr Adolesc Med. 1994;148:1295-1301)

×